Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early after Surgical Bioprosthetic Valve Replacement: the ENBALV trial
Chisato Izumi,Masashi Amano,Satsuki Fukushima,Hitoshi Yaku,Kiyoyuki Eishi,Taichi Sakaguchi,Nobuhisa Ohno,Arudo Hiraoka,Kenji Okada,Yoshikatsu Saiki,Takashi Miura,Tatsuhiko Komiya,Manabu Minami,Haruko Yamamoto,Katsuhiro Omae
DOI: https://doi.org/10.1101/2024.10.16.24315630
2024-10-18
Abstract:Background
Anticoagulant therapy with vitamin K antagonists is recommended in the current guidelines for 3 to 6 months following bioprosthetic valve replacement to prevent thromboembolic events, including in patients with sinus rhythm. However, in the era of direct oral anticoagulants (DOACs), there is a paucity of evidence regarding the efficacy and safety of DOACs in this patient group.
Methods
The ENBALV trial was an investigator-initiated, phase 3, randomized, open-label, multicenter study that aimed to evaluate the efficacy and safety of edoxaban compared to warfarin within 3 months following bioprosthetic valve replacement at the aortic and/or mitral position. The primary outcome was stroke or systemic embolism. The secondary outcomes included major bleeding, intracardiac thrombus, and a composite of stroke, systemic embolism, or major bleeding.
Results
Of 410 enrolled patients, 389 were included in the final analysis (73±6 years, 56.8% male, 79.4% sinus rhythm, edoxaban group: n=195, warfarin group: n=194). The primary outcome occurred in 0.5% (n=1) in the edoxaban group, whereas in 1.5% (n=3) in the warfarin group (risk difference, −1.03, 95% confidence interval [CI], −4.34 to 1.95). Major bleeding occurred in 4.1% (n=8) in the edoxaban group and in 1.0% (n=2) in the warfarin (risk difference, 3.07; 95% CI, −0.67 to 7.27). The incidence of major bleeding was numerically higher in the edoxaban group, but no fatal bleeding or intracranial hemorrhage was observed in patients treated with edoxaban, whereas one fatal intracranial hemorrhage occurred in the warfarin group. Intracardiac thrombus did not occur in any of the patients in the edoxaban group, but did occur in 1.0% (n=2) in the warfarin group.
Conclusions
Edoxaban had comparable efficacy to warfarin for the prevention of thromboembolic events in patients early after bioprosthetic valve replacement, suggesting that it is a potential alternative anticoagulant therapy.